top of page

PUBLICATIONS

This page features NeoVac’s scientific outputs. Peer-reviewed papers, conference presentations, posters and other publications. For company news and announcements, please see News.

1

Safety, tolerability, and immunogenicity of NeomiVac, a next-generation mRNA–lipid nanoparticle vaccine comprising a novel ionisable lipid: a first-in-human, phase 1, dose escalation trial

Papers.ssrn.com

2

Advanced Quality and Comparability Assessment of mRNA-Loaded Lipid Nanoparticles

ACS Publications

3

The impact of chemical reactivity on the quality and stability of RNA–LNP pharmaceuticals

4

Lipid Nanoparticles With Fine-Tuned Composition Show
Enhanced Colon Targeting as a Platform for mRNA Therapeutics

Advanced Science

5

Novel Bivalent mRNA-LNP Vaccine for Highly Effective
Protection against Pneumonic Plague

Advanced Science

6

Ionizable Lipids with Optimized Linkers Enable Lung-Specific, Lipid Nanoparticle Mediated mRNA Delivery for Treatment of Metastatic Lung Tumors

7

A single-dose F1-based mRNA-LNP vaccine provides
protection against the lethal plague bacterium

Science Advances

8

A Combinatorial Library of Lipid Nanoparticles for RNA
Delivery to Leukocytes

Advanced Materials

9

Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery

ACS Applied Nano Materials

10

Inside NeoVac's LNP Formulation Strategy: Challenges, Innovation, And What Comes Next

bottom of page